Skip to main content Skip to search Skip to main navigation
News: Europe

European Commission: Steps to Ensure the Availability of Medicines

On 24 October 2023, the European Commission adopted steps to prevent drug shortages and increase the security of supply in the European Union.

Following supply disruptions in the EU lately, the Commission, with the help of other authorities and associations, has developed a set of measures to prevent critical shortages of key medicines in the future.

In preparation, the European Health Emergency Preparedness and Response Authority (HERA) and the European Medicines Agency (EMA) have already identified the key antibiotics expected to face shortages during the winter months.

In addition, the following measures have been and are being taken:

  • a voluntary solidarity mechanism allows member states to share medicines among themselves
  • a Union list of critical medicines will be established to identify weak links in the supply chain
  • regulatory flexibilities to ensure rapid access to medicines
  • EU guidelines on drug procurement to increase security of supply
  • a joint procurement of antibiotics and respiratory therapeutics on EU level for the next winter

Regulatory flexibilities for essential medicines are expected to be a key element. This is specifically aimed to accelerate the approval and introduction of alternative medicines, to increase production and approval of alternative suppliers, to temporarily extend the shelf life of products, and to allow for the redistribution of medicines between member states.

The European Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) has provided further insight into how these flexibilities will be applied this winter. Competent authorities will decide on a case-by-case basis whether recommendations will be implemented.

To secure the long-term supply of medicines, the Commission plans to establish a Critical Medicines Alliance that will focus on particularly important medicines. This alliance will include measures to diversify manufacturing and modernize supply chains. It is expected to be launched early next year.

The availability of medicines worldwide requires international cooperation and partnerships, including with third countries.


Source:

EC: Press release

 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may Also be Interested in the Following Articles

News: Medical Devices

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.
Read more
PIC/S: Revision of the Framework for International Cooperation

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.
Read more
FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA has revised its framework for collaboration between the Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). Version 2.0 of the Concept of Operations (ConOps), effective October 21, 2026, supersedes the original June 2017 version.
Read more
Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

For any outsourced GDP activity, there is a need for delimitation of responsibilities between a client (contract giver) and a contractor (contract acceptor). Read more about their roles and responsibilities in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
Question of the Week | GMP-Verlag

Who is Qualified to Conduct Self-Inspections within a Company?

Here's the question:
Read more
News: Europe

EU: Singapore Added to List of Recognised Third Countries for API Importation

The European Commission recognises Singapore’s GMP requirements and regulatory oversight of active substance manufacturers as equivalent to EU requirements. Once the decision enters into force (15 November), Singapore will join the EU list of recognised third countries for the importation of active substances.
Read more
Previous
Next